S. Gremlich, A. Porret, E. H. Hani, D. Cherif, N. Vionnet et al., , p.675

B. , Cloning, functional expression, and chromosomal localization of the human 676 pancreatic islet glucose-dependent insulinotropic polypeptide receptor, Diabetes, vol.44, pp.1202-677, 1995.

A. M. Habib, P. Richards, L. S. Cairns, G. J. Rogers, C. A. Bannon et al.,

T. C. Morley, G. S. Yeo, F. Reimann, and F. M. Gribble, Overlap of endocrine 680 hormone expression in the mouse intestine revealed by transcriptional profiling and flow 681 cytometry, Endocrinology, vol.153, pp.3054-65, 2012.

C. Hamann, M. Rauner, Y. Hohna, R. Bernhardt, J. Mettelsiefen et al.,

K. P. Gunther, M. Stolina, C. Y. Han, and F. J. Asuncion, Sclerostin antibody 684 treatment improves bone mass, bone strength, and bone defect regeneration in rats with 685 type 2 diabetes mellitus, J Bone Miner Res, vol.28, pp.627-665, 2013.

L. Hegedus, A. C. Moses, M. Zdravkovic, T. Le-thi, and G. H. Daniels, GLP-1 and 687 calcitonin concentration in humans: lack of evidence of calcitonin release from sequential 688 screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated 689 with the human GLP-1 analog, liraglutide, J Clin Endocrinol Metab, vol.96, pp.853-60, 2011.

J. J. Holst and C. F. Deacon, Glucagon-like peptide-1 mediates the therapeutic actions 691 of DPP-IV inhibitors, Diabetologia, vol.48, pp.612-617, 2005.

E. W. Iepsen, J. R. Lundgren, B. Hartmann, O. Pedersen, T. Hansen et al.,

L. B. Jensen, F. Quaade, and O. H. Sorensen, Bone loss accompanying voluntary 703 weight loss in obese humans, J Bone Miner Res, vol.9, pp.459-63, 1994.

M. J. Jespersen, F. K. Knop, and M. Christensen, GLP-1 agonists for type 2 diabetes: 705 pharmacokinetic and toxicological considerations, Expert Opin Drug Metab Toxicol, vol.9, pp.17-29, 2013.

S. Kainuma, H. Tokuda, K. Fujita, T. Kawabata, G. Sakai et al.,

R. Harada, A. Kozawa, O. Otsuka, and T. , Attenuation by incretins of thyroid 708 hormone-stimulated osteocalcin synthesis in osteoblasts, Biomed Rep, vol.5, pp.771-775, 2016.

R. Khosravi, K. L. Sodek, M. Faibish, and P. C. Trackman, Collagen advanced 710 glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl 711 oxidase in osteoblasts, Bone, vol.58, pp.33-41, 2014.

J. Y. Kim, S. K. Lee, K. J. Jo, D. Y. Song, D. M. Lim et al.,

J. , Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially 714 through the down-regulation of SOST/sclerostin in osteocytes, Life Sci, vol.92, pp.533-573, 2013.

J. C. Krakauer, M. J. Mckenna, N. F. Buderer, D. S. Rao, and F. W. Whitehouse,

A. M. Parfitt, Bone loss and bone turnover in diabetes, Diabetes, vol.44, pp.775-82, 1995.

T. Kubota, N. Kubota, H. Kumagai, S. Yamaguchi, H. Kozono et al.,

M. Inoue, S. Itoh, I. Takamoto, and T. Sasako, Impaired insulin signaling in 719 endothelial cells reduces insulin-induced glucose uptake by skeletal muscle, Cell Metab, vol.13, pp.294-307, 2011.

Y. Lamari, C. Boissard, M. S. Moukhtar, A. Jullienne, G. Rosselin et al.,

H. M. Lee, B. S. Joo, C. H. Lee, H. Y. Kim, J. H. Ock et al., Effect of Glucagon-729 like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts, p.730, 2015.

, Adipocytes. J Menopausal Med, vol.21, pp.93-103

N. K. Lee, H. Sowa, E. Hinoi, M. Ferron, J. D. Ahn et al.,

P. J. Mee, M. D. Mckee, and D. Y. Jung, Endocrine regulation of energy 733 metabolism by the skeleton, Cell, vol.130, pp.456-69, 2007.

R. Li, W. Xu, S. Luo, H. Xu, G. Tong et al., Effect of 735 exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed 736 type 2 diabetes, Acta Diabetol, vol.52, pp.1083-91, 2015.

R. T. Loder, The influence of diabetes mellitus on the healing of closed fractures, Clin, vol.738, 1988.

, Orthop Relat Res, pp.210-216

N. Lu, H. Sun, J. Yu, X. Wang, D. Liu et al., , 2015.

, Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in 741 ovariectomized rats without diabetes, PLoS One, vol.10, p.132744

M. E. Lunati, V. Grancini, C. Colombo, E. Palmieri, V. Resi et al.,

L. Fugazzola, Basal and stimulated calcitonin levels in patients with type 2 diabetes 744 did not change during 1 year of Liraglutide treatment, Metabolism, vol.65, pp.1-6, 2016.

X. Ma, J. Meng, M. Jia, L. Bi, Y. Zhou et al., Exendin-746 4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone 747 formation and suppressing bone resorption in aged ovariectomized rats, J Bone Miner Res, vol.748, pp.1641-52, 2013.

G. Mabilleau, A. Mieczkowska, N. Irwin, P. R. Flatt, and D. Chappard, Optimal 755 bone mechanical and material properties require a functional glucagon-like peptide-1 756 receptor, J Endocrinol, vol.219, pp.59-68, 2013.

G. Mabilleau, R. Perrot, P. R. Flatt, N. Irwin, and D. Chappard, High fat-fed 758 diabetic mice present with profound alterations of the osteocyte network, Bone, vol.90, pp.99-106, 2016.

S. A. Mansur, A. Mieczkowska, B. Bouvard, P. R. Flatt, D. Chappard et al.,

G. Mabilleau, Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality 761 in Type 1 Diabetes Mellitus, J Cell Physiol, vol.230, pp.3009-3027, 2015.

C. H. Mcintosh, S. Widenmaier, and S. J. Kim, Pleiotropic actions of the incretin 763 hormones, Vitam Horm, vol.84, pp.21-79, 2010.

J. Meng, X. Ma, N. Wang, M. Jia, L. Bi et al., Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic 766 Differentiation through beta-Catenin, Stem Cell Reports, vol.6, p.633, 2016.

A. Mieczkowska, N. Irwin, P. R. Flatt, D. Chappard, and G. Mabilleau, Glucose-768 dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone 769 strength and quality, Bone, vol.56, pp.337-379, 2013.

A. Mieczkowska, S. Mansur, B. Bouvard, P. R. Flatt, B. Thorens et al.,

D. Chappard and G. Mabilleau, Double incretin receptor knock-out (DIRKO) mice 772 present with alterations of trabecular and cortical micromorphology and bone strength, 2015.

D. Naot, D. S. Musson, and J. Cornish, The Activity of Adiponectin in Bone, 2017.

, Tissue Int, vol.100, pp.486-499

N. Napoli, M. Chandran, D. D. Pierroz, B. Abrahamsen, A. V. Schwartz et al., , p.785

S. L. Bone, I. O. Diabetes-working, and G. , Mechanisms of diabetes mellitus-786 induced bone fragility, Nat Rev Endocrinol, 2016.

B. Nuche-berenguer, D. Lozano, I. Gutierrez-rojas, P. Moreno, and M. L. Marinoso,

P. Esbrit and M. L. Villanueva-penacarrillo, GLP-1 and exendin-4 can reverse 789 hyperlipidic-related osteopenia, J Endocrinol, vol.209, pp.203-213, 2011.

B. Nuche-berenguer, P. Moreno, S. Portal-nunez, S. Dapia, and P. Esbrit,

M. L. Villanueva-penacarrillo, Exendin-4 exerts osteogenic actions in insulin-792 resistant and type 2 diabetic states, Regul Pept, vol.159, pp.61-67, 2010.

B. Nuche-berenguer, S. Portal-nunez, P. Moreno, N. Gonzalez, and A. Acitores,

A. Lopez-herradon, P. Esbrit, I. Valverde, and M. L. Villanueva-penacarrillo, , 2010.

, Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-796 linked GLP-1 receptor, J Cell Physiol, vol.225, pp.585-92

T. Nystrom, M. K. Gutniak, Q. Zhang, F. Zhang, J. J. Holst et al.,

A. , Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes 799 patients with stable coronary artery disease, Am J Physiol Endocrinol Metab, vol.287, pp.1209-1224, 2004.

M. S. Ominsky, F. Vlasseros, J. Jolette, S. Y. Smith, B. Stouch et al.,

J. Gong, Y. Gao, J. Cao, and K. Graham, Two doses of sclerostin antibody in 802 cynomolgus monkeys increases bone formation, bone mineral density, and bone strength, 2010.

T. M. Link, Increased cortical porosity in type 2 diabetic postmenopausal women with, 2013.

M. Saito, K. Fujii, Y. Mori, and K. Marumo, Role of collagen enzymatic and glycation 837 induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob 838 rats, Osteoporos Int, vol.17, pp.1514-1537, 2006.

A. V. Schwartz, P. Garnero, T. A. Hillier, D. E. Sellmeyer, and E. S. Strotmeyer,

K. R. Feingold, H. E. Resnick, F. A. Tylavsky, D. M. Black, and S. R. Cummings, Pentosidine and increased fracture risk in older adults with type 2 diabetes, J Clin, vol.842, 2009.

, Endocrinol Metab, vol.94, pp.2380-2386

A. V. Schwartz, T. A. Hillier, D. E. Sellmeyer, H. E. Resnick, E. Gregg et al.,

P. J. Schreiner, K. L. Margolis, J. A. Cauley, and M. C. Nevitt, Older women 845 with diabetes have a higher risk of falls: a prospective study, Diabetes Care, vol.25, pp.1749-54, 2002.

A. V. Schwartz, E. Vittinghoff, D. C. Bauer, T. A. Hillier, and E. S. Strotmeyer,

K. E. Ensrud, M. G. Donaldson, J. A. Cauley, T. B. Harris, and A. Koster, , 2011.

, Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes

, JAMA, vol.305, pp.2184-92

A. V. Schwartz, E. Vittinghoff, D. E. Sellmeyer, K. R. Feingold, and N. De-rekeneire, , p.851

E. S. Strotmeyer, R. I. Shorr, A. I. Vinik, M. C. Odden, and S. W. Park, , 2008.

, Diabetes-related complications, glycemic control, and falls in older adults, Diabetes Care, vol.31, pp.391-397

D. E. Sellmeyer, R. Civitelli, L. C. Hofbauer, S. Khosla, and B. Lecka-czernik,

A. V. Schwartz, Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 856 1 and Type 2 Diabetes, Diabetes, vol.65, pp.1757-66, 2016.

A. Shu, M. T. Yin, E. Stein, S. Cremers, E. Dworakowski et al., Bone structure and turnover in type 2 diabetes mellitus, Osteoporos Int, vol.23, pp.635-676, 2012.

M. M. Smits, M. H. Muskiet, L. Tonneijck, M. H. Kramer, M. Diamant et al.,

D. H. Serne, E. H. Su, B. Sheng, H. Zhang, M. Bu et al., GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion, 2015.

J. Wang, Risk of bone fractures associated with glucagon-like peptide-1 receptor 865 agonists' treatment: a meta-analysis of randomized controlled trials, Endocrine, vol.48, pp.107-122, 2015.

A. Sufiun, K. Rafiq, Y. Fujisawa, A. Rahman, H. Mori et al.,

K. Ohmori, T. Masaki, and M. Kohno, Effect of dipeptidyl peptidase-4 inhibition 868 on circadian blood pressure during the development of salt-dependent hypertension in rats, 2015.

A. Wang, T. Li, P. An, W. Yan, H. Zheng et al., , 2017.

, Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. PLoS One, 892 like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats, Cardiovasc Diabetol, vol.918, p.29